<DOC>
	<DOCNO>NCT00204659</DOCNO>
	<brief_summary>The optimal treatment primary gastric diffuse large B-cell lymphoma ( PG-DLBCL ) yet define . In circumstance , stomach-conserving approach favor , role radiotherapy still matter debate . Recently , Rituximab along full-dose CHOP chemotherapy show improve outcome elderly patient nodal DLBCL . However , data available therapy patient PG-DLBCL . Therefore , March 2003 , initiate ongoing , prospective , multicenter phase II study patient PG-DLBCL 6 8 cycle Rituximab ( R ; 375 mg/m2 ) plus CHOP-21 order evaluate safety efficacy approach .</brief_summary>
	<brief_title>Phase II Study With Rituximab Cyclophosphamide , Doxorubicin , Vincristine , Prednisone ( CHOP ) Patients With Gastric Diffuse Large B-Cell Non-Hodgkin ` Lymphoma</brief_title>
	<detailed_description>see</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age &gt; 18 year Histologically confirm primary gastric CD20+ DLBCL Written inform consent ECOG 02 Secondary aggressive NonHodgkin ` lymphoma involve gastric area HIV positive patient Severe organ dysfunction Life expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>CHOP</keyword>
	<keyword>DLBCL</keyword>
	<keyword>gastric lymphoma</keyword>
</DOC>